drugset / Trial / NCT00502528

Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction

NCT00502528

Phase 2 Completed 57 enrolled Medical University of Vienna
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Background and Objective: Acute coronary syndrome is characterized by compromised blood flow at the epicardial and microvascular levels. The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients with STEMI. Patients are randomized to receive periinterventional intravenous BQ-123 or placebo.

Timeline

Start
2007-05
Primary completion
2009-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator BQ-123 Peptide 400 unknown Intravenous